Skip to NavigationSkip to content

Eusa Pharma appoints Iain McGill

Published on: 10/03/10

Iain McGill has joined specialty company Eusa Pharma as international and European president.

He moves to Eusa from Wyeth Pharmaceutical, where he was vice president and global manager for its transplantation business.

Prior to this he was head of Novartis’ Transplantation, Immunology and Infectious Diseases business unit in Canada, and before that a global brand director at Novartis’ headquarters in Switzerland.

He has also held a number of sales and marketing positions of increasing seniority at Novartis and Roche in the UK.

The company said McGill’s appointment finalised its executive management team and commercial infrastructure.

“We are delighted to welcome Iain to EUSA at such an exciting time in the company’s development,” said Bryan Morton, Eusa Pharma’s president and chief executive.

“Since founding Eusa four years ago, we have made tremendous progress, raising over $300 million in investment funding, establishing a portfolio of eight marketed and four pipeline products, and building a strong commercialisation platform on both sides of the Atlantic.”

Eusa now has a presence in over 80 countries, with teams covering the US and over 20 European territories including the major EU markets, and the company anticipates strong sales growth and profitability in 2010.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches